The measurement of human T-cell leukemia virus type 1 (HTLV-1) proviral DNA levels by using polymerase chain reaction has been beneficial for confirming HTLV-1 infection during pregnancy. However, the influence of pregnancy on HTLV-1 infection and proviral DNA levels among pregnant women with HTLV-1 has not been clarified. We prospectively gathered blood samples from 36 pregnant women in whom HTLV-1 carriage was previously diagnosed and sequentially measured their proviral DNA levels. The HTLV-1 proviral DNA levels remained at a plateau during pregnancy but were elevated after delivery. Moreover, flow cytometry and serological analyses revealed that the regulatory T-cell population and soluble interleukin 2 receptor levels were similarly elevated after birth in comparison with those in control pregnant women. This study is the first to provide data on sequential changes in HTLV-1 proviral DNA levels during and after pregnancy. These findings will guide the establishment of a better program to prevent mother-to-child transmission of HTLV-1.
Human T-cell leukemia virus type 1 (HTLV-1; also known as human T-lymphotropic virus type 1) is the causative agent of adult T-cell leukemia-lymphoma and HTLV-1-associated myelopathy. Despite recent improvements in treatment modalities, the prognosis of patients with adult T-cell leukemia-lymphoma remains poor [1] . A cohort study on HTLV-1 carriers indicated that infection during childhood is a potential risk factor for the development of adult T-cell leukemia-lymphoma [2] . Furthermore, the most important route of HTLV-1 infection was found to be mother-to-child transmission through breastfeeding [3, 4] . Based on this finding, in Nagasaki Prefecture, which is one of the areas in Japan where HTLV-1 endemicity is highest, prefecture-wide antenatal screening for HTLV-1 to identify women who should avoid breastfeeding started in 1987 [4] . Recently, as HTLV-1 carriage spread in Japan, nationwide screening of pregnant women for HTLV-1 infection has been recommended to prevent breast milk-borne transmission of HTLV-1 since 2011, and the results of this screening estimate that annually there are 1620 HTLV-1 carriers among Japanese pregnant women, accounting for 0.16% of this population [5] .
Screening tests for HTLV-1 infection are primarily performed using serological methods, such as particle agglutination or chemiluminescent enzyme immunoassay, to detect antibodies against HTLV-1. Western blotting is typically performed afterward as a confirmatory test for samples with positive screening results, and this assay requires the detection of antibodies against both gag and env viral gene products. However, some individuals with a positive serological result can have an indeterminate Western blotting result due to incomplete antibody reactivity to HTLV-1 antigens. This discrepancy between the screening result and the confirmatory result is one of the issues that need to be resolved for optimization of the antenatal screening system for HTLV-1 infection during pregnancy, as well as a similar screening system for blood donors [6, 7] . Polymerase chain reaction (PCR)-based testing to detect the proviral DNA genome of HTLV-1 in peripheral blood mononuclear cells (PBMCs) has previously been performed as an alternative diagnostic test for the general population, such as blood donors [8] [9] [10] . However, the sequential proviral DNA levels in HTLV-1 carriers during and after pregnancy have not yet been reported.
Regulatory T cells (Tregs), a small subset of CD4 + T cells that are regulated by the forkhead box P3 (FoxP3) gene, are required for the maternal immune system to achieve tolerance of the fetal allograft and play an important role in the development and maintenance of pregnancy [11, 12] . Interestingly, HTLV-1 is frequently detectable in CD4 + FoxP3 + Tregs in asymptomatic HTLV-1 carriers. Tregs have been focused on as the possible origin of HTLV-1-infected cells [13, 14] . Moreover, the number of HTLV-1-infected cells among asymptomatic carriers has been reported to correlate with levels of soluble interleukin 2 receptor (sIL-2R), which is an activated T-cell marker [15] . However, it is unclear how the status of pregnancy affects individuals with an HTLV-1 infection.
In this study, we prospectively conducted a longitudinal analysis of pregnant HTLV-1 carriers in Nagasaki Prefecture to clarify the sequential changes in HTLV-1 proviral DNA levels, the Treg population, and sIL-2R levels that occur during pregnancy and the postpartum period.
METHODS

Study Design and Population
This study was conducted from October 2013 to December 2015 at Nagasaki University Hospital and regional clinics in Nagasaki Prefecture. Using screening tests for HTLV-1 infection in pregnant women, 110 of 12 941 pregnant women (0.85%) had been diagnosed as HTLV-1 carriers. Pregnant women with a diagnosis of either HTLV-1 carrier (n = 36) or HTLV-1 negativity (n = 17) were included in this study (Table 1 ) because sequential sampling throughout pregnancy was possible as consecutive cases. The 36 eligible HTLV-1 carriers participating in this study were those who already knew of their HTLV-1 infection from a previous HTLV-1 screening (maternal screening or blood donor screening), and they were reconfirmed as having an HTLV-1 infection in the screening test performed at 28-30 weeks of gestation. Blood samples were sequentially obtained from each pregnant participant, regardless of HTLV-1 carrier status, during the 4 stages of pregnancy: the first trimester (samples were collected at 10-12 weeks of gestation), the second trimester (collected at 22-24 weeks of gestation), the third trimester (collected at 34-36 weeks of gestation), and the postpartum period (collected at 1 month after childbirth). This study was approved by the Institutional Review Board for Ethical, Legal, and Social Issues of Nagasaki University, and all samples were obtained after participants provided written informed consent.
Sample Collection and Preparation
Peripheral blood samples were collected in ethylenediaminetetraacetic acid-lined and heparinized containers. The resulting serum samples were used for the measurement of sIL-2R. Whole PBMCs were isolated by Ficoll-Hypaque density gradient centrifugation (Lymphoprep; Axis-Shield, Oslo, Norway) according to the manufacturer's instructions. Freshly isolated PBMCs were used for flow cytometry. DNA was extracted from PBMCs by using a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. These DNA samples were stored at −80°C until measurement of the HTLV-1 proviral DNA level.
Measurement of the HTLV-1 Proviral DNA Level
Quantitative digital PCR analysis was performed for the sequential measurements of HTLV-1 proviral load. Digital-droplet PCR (ddPCR) was previously evaluated as a potentially more reliable tool for HTLV-1 proviral DNA quantification [16] , so this method was used here. The primers and probes used for the ddPCR analysis of HTLV-1 have been previously reported [8, 10] . The primers were set in the pX region, and the density of the DNA template was 100 ng per reaction. The primers and probes of HTLV-1 were as follows: 5ʹ-CCCACTTCCCAGGGTTTGGA-3ʹ (forward), 5ʹ-GGCCAGTAGGGCGTGA-3ʹ (reverse), and FAM-5ʹ-CCAGTCTACGTGTTTGGAGACTGTGTACA-3ʹ-BHQ (probe). The PCR mixture was prepared using a 2× ddPCR supermix for probes (Bio-Rad, Hercules, CA). Droplets were prepared on a QX100 droplet generator (Bio-Rad). PCR was performed with a thermal cycler (Bio-Rad) and detected with a QX100 droplet reader (Bio-Rad). All sequential samples for each pregnant woman were measured on the same PCR plate. Data are shown as the means of triplicate analysis. The HTLV-1 proviral DNA levels was normalized using β-globin genes as an internal control and are expressed as pX copy numbers per 100 PBMCs (%), based on the assumption that infected cells each harbored 1 pX copy of the integrated HTLV-1 provirus and 2 internal control gene copies per cell [8] . The results are presented as median (range) copies per 100 PBMCs (%).
Flow Cytometry
Freshly isolated PBMCs (1 × 10 6 cells) were stained with PE-Cy7-labeled anti-CD45, APC-H7-labeled anti-CD3, PerCP-labeled anti-CD4, APC-labeled anti-CD25, and FITClabeled anti-CD127 (BD Biosciences, San Jose, CA). Samples were measured by a FACS Canto II system (BD Biosciences) and were analyzed using BD FACS Diva software, version 1.47 (BD Biosciences).
Measurement of sIL-2R
Concentrations of serum sIL-2R were measured by a chemiluminescent enzyme immunoassay, using the Immulyze IL-2R II reagent (Siemens Healthcare Diagnostics, Erlangen, Germany), according to the manufacturer's instructions.
Statistical Analysis
Statistical analyses were performed using SPSS, version 23 (IBM, Armonk, NY). The median proviral DNA levels in 2 different periods were compared using a Wilcoxon signed rank test, whereas comparisons among ≥3 periods were made using a Kruskal-Wallis test. The comparisons between HTLV-1-positive and HTLV-1-negative pregnant women were performed using the Mann-Whitney U test. A P value of <.05 was accepted as statistically significant.
RESULTS
HTLV-1 Proviral DNA Levels Plateaued During Pregnancy and Increased
After Delivery
The clinical characteristics of this study population are shown in Table 1 . The HTLV-1 proviral DNA level among the enrolled pregnant HTLV-1 carriers exhibited a nonparametric distribution and a very wide range (Supplementary Figure 1) . Therefore, we divided these 36 participants into the following 2 groups, based on their proviral DNA level in the postpartum period: high (n = 18; ≥0.5%) and low (n = 18; <0.5%). Figure 1 shows the sequential change in the HTLV-1 proviral DNA level during pregnancy and the postpartum period in the low group and the high group. In the low group ( Figure 1A) , median HTLV-1 proviral DNA levels were 0.046% (range, 0%-0.43%) in the first trimester of pregnancy, 0.074% (range, 0%-0.44%) in the second trimester, 0.091% (range, 0.0042%-0.79%) in the third trimester, and 0.15% (range, 0.0042%-0.49%) 1 month after childbirth. In the high group (Figure 1B) , the median HTLV-1 proviral DNA levels were 0.56% (range, 0.10%-4.4%) in the first trimester of pregnancy, 0.64% (range, 0.081%-2.2%) in the second trimester, 0.58% (range, 0.072%-3.2%) in the third trimester, and 1.5% (0.50%-4.7%) 1 month after childbirth. In the first, second, and third trimesters of pregnancy, there were no significant differences among the HTLV-1 proviral DNA levels during pregnancy (P > .05, by the Kruskal-Wallis test); however, statistically significant differences in HTLV-1 proviral DNA levels were found between samples collected during pregnancy (ie, during the first, second, and third trimesters) and those taken after delivery (ie, 1 month after childbirth) in both the low and high groups (P < .05, by the Wilcoxon signed rank test). The analysis using the undivided data of Bold lines indicate median proviral DNA levels. Thirty-six pregnant women were divided into 2 groups on the basis of their postpartum HTLV-1 proviral DNA levels: low (A) and high (B). There were no significant differences in the HTLV-1 proviral DNA levels during pregnancy (P > .05, by the Kruskal-Wallis test, for both groups). There were statistically significant differences in HTLV-1 proviral DNA levels between pregnancy (ie, during the first, second, and third trimesters) and 1 month after childbirth in both groups (*P < .05, by the Wilcoxon signed rank test). PBMC, peripheral blood mononuclear cell.
the HTLV-1 proviral DNA levels among all pregnant HTLV-1 carriers (both low and high groups) showed the same result as described above (Supplementary Figure 2) .
Sequential Differences in Tregs and sIL-2R Levels Between HTLV-1-
Positive and HTLV-1-Negative Pregnant Women
CD127 expression inversely correlates with FoxP3 [17] ; as expected, the CD4 + CD25 + CD127 low/− population contained FoxP3-positive Tregs (Figure 2A) . To investigate whether pregnancy affected these cells in HTLV-1 carriers, we compared the amounts of CD4 + CD25 + CD127 low/− T cells and levels of sIL-2R at several periods of pregnancy between 27 pregnant HTLV-1 carriers and 17 HTLV-1-negative pregnant women. The median percentages of CD4 + CD25 + CD127 low/− cells in the CD4 + T-cell population in pregnant HTLV-1 carriers and HTLV-1-negative pregnant women were 5.9% (range, 1.4%-15.0%) and 5.8% (range, 1.9%-9.9%), respectively, in the first trimester of pregnancy; 6.1% (range, 2.5%-13.7%) and 6.15% (range, 4.4%-8.7%), respectively, in the second trimester; 6.5% (range, 3.5%-19.0%) and 6.1% (range, 3.9%-9.0%), respectively, in the third trimester; and 7.95% (range, 4.1%-14.6%) and 6.6% (range, 5.0%-9.0%), respectively, 1 month after childbirth ( Figure 2B ). Neither group had significant differences in the CD4 + CD25 + CD127 low/− population over the course of pregnancy; however, the proportion of this cell population was significantly higher in pregnant HTLV-1 carriers than in HTLV-1-negative pregnant women in the postpartum period (P = .009, by the Mann-Whitney U test; Figure 2B ). In pregnant HTLV-1 carriers and HTLV-1-negative pregnant women, there were no significant differences in the CD4 + CD25 + CD127 low/− population during and after pregnancy (P > .05, by the KruskalWallis test; Figure 2B ). The median sIL-2R levels in pregnant The CD4 + CD25 + CD127 low/− population was significantly higher among the pregnant HTLV-1 carriers than among the HTLV-1-negative pregnant women in the postpartum period (*P < .05, by the Mann-Whitney U test). In pregnant HTLV-1 carriers and HTLV-1-negative pregnant women, there were no significant differences in the CD4 + CD25 + CD127 low/− population during and after pregnancy (P > .05, by the Kruskal-Wallis test). The sIL-2R levels were also significantly higher among the pregnant HTLV-1 carriers in the postpartum period (*P < .05, by the Mann-Whitney U test). The sIL-2R levels in the third trimester of pregnancy were significantly lower than in the first trimester of pregnancy among pregnant HTLV-1 carriers and HTLV-1-negative pregnant women (*P < .05, by the Mann-Whitney U test). SSC, side scatter.
HTLV-1 carriers and HTLV-1-negative pregnant women were 268.5 U/mL (range, 176-742 U/mL) and 254 U/mL (range, 180-431 U/mL), respectively, in the first trimester of pregnancy; 209 U/mL (range, 148-455 U/mL) and 215.5 U/mL (range, 112-423 U/mL), respectively, in the second trimester; 196 U/mL (range, 127-390 U/mL) and 196.5 U/mL (range, 103-426 U/mL), respectively, in the third trimester; and 311 U/mL (range, 148-640 U/mL) and 236 U/mL (range, 146-322 U/mL), respectively, 1 month after childbirth ( Figure 2C ). The sIL-2R levels were also significantly higher in pregnant HTLV-1 carriers than in HTLV-1-negative pregnant women in the postpartum period (P = .032, by the Mann-Whitney U test; Figure 2C) . Moreover, the sIL-2R levels showed a tendency to decrease over the course of pregnancy and to restore after delivery; the sIL-2R levels in the third trimester of pregnancy were significantly lower than in the first trimester of pregnancy in both pregnant HTLV-1 carriers and HTLV-1-negative pregnant women (P = .014 and P = .029, respectively, by the Mann-Whitney U test; Figure 2C ). Neither group showed significant differences in the sIL-2R levels between in the first trimester of pregnancy and 1 month after childbirth (P > .05, by the Mann-Whitney U test; Figure 2C ).
DISCUSSION
The course of HTLV-1 proviral DNA transition during and after pregnancy has not been previously described. This study measured proviral DNA levels sequentially among HTLV-1 carriers during pregnancy. Briefly, regardless of each participant's exact proviral DNA levels, their HTLV-1 proviral DNA levels plateaued during pregnancy and were elevated after delivery. These patterns are consistent with our flow cytometry and serological findings. HTLV-1 proviral DNA levels among asymptomatic pregnant HTLV-1 carriers exhibited a very wide range, from 0.0042% during the first trimester to 4.7% in the postpartum period, similar to the wide distribution of HTLV-1 proviral DNA levels in the general population [18, 19] . Therefore, we analyzed the patients' HTLV-1 proviral levels after dividing them into 2 groups (high and low) on the basis of these levels. In both high and low groups, HTLV-1 proviral levels plateaued during pregnancy and increased after delivery. The proviral DNA levels among asymptomatic HTVL-1 carriers in the general population were found to remain stable at the individual level during a long follow-up period [18, 19] . A previous study comparing the HTLV-1 proviral DNA levels between a seroconverter and their spouse showed that host factors appear to be important in the determination of proviral DNA levels in HTLV-1 carriers [20] . Moreover, a prospective long-term analysis among seroconverters after HTLV-1 infection revealed that a small change in proviral DNA levels occurs sequentially soon after infection [18, 21] . Following HTLV-1 infection, a new cell-to-cell infection occurs infrequently in stable individuals because of their immune response. Instead, increased HTLV-1 proviral DNA levels have mainly been achieved by the clonal proliferation of infected cells [22] .
Owing to the dramatic changes in immune tolerance that occur during pregnancy and childbirth, the proliferation of HTLV-1-infected Tregs may contribute to the elevated HTLV-1 proviral DNA level that is observed after delivery. This finding is consistent with the larger population of Tregs and the higher sIL-2R levels detected in HTLV-1 carriers than in HTLV-1-negative women during the postpartum period. Here, the significantly higher postpartum sIL-2R levels among HTLV-1 carrier women, compared with that among HTLV-1-negative women, may act to increase the number of HTLV-1-infected cells, which is consistent with the observed increase in the HTLV-1 proviral DNA level in the postpartum period. Presently, the detailed mechanism responsible for this phenomenon remains unidentified. A longterm cohort study of children who acquired HTLV-1 infection perinatally suggested that HTLV-1 infects T cells through the stimulation of an immune response (eg, an immune response caused by eczema could lead to the clonal expansion of HTLV-1-infected cells) [23] . In addition, we found that sIL-2R levels showed a tendency to decrease with the progression of pregnancy and to restore after delivery but that the Treg cell population did not show a significant change. We propose that the end of immune tolerance mechanisms after delivery causes a clonal expansion of HTLV-1-infected cells. Further studies are needed to clarify how pregnancy affects the status of HTLV-1 infection.
A major limitation in our study is that the follow-up period for HTLV-1 carriers was only up to 1 month after childbirth. Therefore, it is not clear whether the observed elevation of proviral DNA levels after delivery is subsequently maintained for several years. Additionally, in the low group, HTLV-1 proviral DNA levels tended to increase as pregnancy progressed, although there was no correlation between the proviral DNA levels and the progression of pregnancy (Figure 1 ). This trend was not clear in the high group. The absence of statistical significance might have been due to the small sample size. In both groups, a cluster of patients with similar HTLV-1 proviral DNA levels was present at all time points, but some outliers had clearly higher HTLV-1 proviral DNA levels than most patients and appeared consistently in both groups, indicating that pregnant HTLV-1 carriers have a wide variation in their proviral DNA levels. The etiology of this wide variation remains unknown; a study with a larger number of participants may clarify the association between pregnancy and the status of the proviral DNA level. Therefore, to resolve the limitations of this study, a long-term observation with a larger number of participants and collection of clinical information throughout pregnancy is necessary.
In conclusion, this study is the first to provide data on the sequential transition of HTLV-1 proviral DNA levels during pregnancy and after delivery. After remaining plateaued during pregnancy, HTLV-1 proviral DNA levels were elevated following delivery. These findings support the use of proviral DNA measurement as a test for confirming HTLV-1 infection in HTLV-1-seropositive pregnant women. Further study to identify the association between maternal HTLV-1 proviral DNA levels and the infectious rate of mother-to-child transmission would establish a better prevention program for mother-to-child transmission of HTLV-1.
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